JANSSEN PARTNERSHIPS FOR INNOVATION IN HEALTH José Antunes Janssen Coimbra 16th April 2015
WE ARE PART OF Janssen is a subsidiary of the Johnson & Johnson, one of the biggest healthcare companies in the world, with more than 125 years of history. More than 200 operating companies, across three different sectors:
GLOBAL INVESTMENT IN R&D (2013) (IN % OF SALES AND IN ABSOLUTE FIGURES) R&D investments (in mln) 80,000 70,000 60,000 50,000 40,000 30,000 20,000 10,000 OIL&GAS FOOD TELCO/ISP CHEMICAL TECHNOLOGY HARDWARE AUTOMOBILE&PARTS SOFTWARE&COMPUTER AEROSPACE LEISURE GOODS PHARMACEUTICALS 5 10 15 20 R&D investments as % of sales Source: EU R&D Industrial Scoreboard, 2013
GLOBAL INVESTMENT IN R&D (2013) Top 20 ranking of companies worldwide based on total investment in R&D Johnson & Johnson ranked 4th in pharma and 9th in all sectors Source: EU R&D Scoreboard 2013
OUR STRATEGY FOR INNOVATION 13 R&D CENTERS 4 INNOVATION CENTERS Source: Janssen 6
THE GROWING ROLE OF EXTERNAL INNOVATION Percentage of drugs under development that were initially developed at another company 50% 33% 16% 20% 2002 2012 2002 2012 Top 10 Pharmaceutical Companies Source: Medtrack; Johnson & Johnson The Wall Street Journal
THE INNOVATION CENTERS CONNECTING TO THE WORLD Close to the innovator Source: Janssen
OUR OBJECTIVES IN J&J INNOVATION CENTERS Catalysts for science and technology innovation between the inventor and Johnson & Johnson Our Goals Bring innovation closer to patients Fuel & accelerate entrepreneurship Integrate with the ecosystem Build trusted relationships in the scientific/inventor community What We Bring to Collaborations Access to expertise, capabilities & platforms Global, cross-sector reach Heritage of caring for patients, families, communities Accelerate external R&D in areas of core interest How we collaborate: Our People together with Partners, preferably on an equal playing field, bringing innovative Products to patients
OUR EXTENDED NETWORK IN EUROPE Source: Janssen
OUR AREAS OF FOCUS Our Janssen Pharmaceutical business is one of the most productive and innovative in the world. In the past 10 years, we have brought more differentiated pharmaceutical products to patients than any other company. The teams at the Johnson & Johnson Innovation Centers are interested in exploring early stage therapeutic and vaccine technologies up to clinical proof of concept in the following areas: Cardiovascular and Metabolism Type 2 Diabetes Heart Failure Infectious Diseases and Vaccines Hepatitis Respiratory Infections Oncology Prostate Cancer Lung Cancer Hematologic Malignancies Immunology Rheumatoid Arthritis Inflammatory Bowel Disease Psoriasis Pulmonary Neuroscience Mood Disorders Alzheimer s Disease Source: Janssen
HOW DO WE SET OUR PRIORITIES Conviction level of experts in science & target Ability to establish pre-clinical and clinical POC Time and cost to preclinical and clinical POC Leadership potential (competitive landscape) Strategic fit for J&J IP strength Collaboration capability of partner Patient impact (medical need) Societal impact (e.g. patient years) Transformative potential at time of launch Cost of access (deal terms) Delivering Clinical POC products Source: Janssen
OUR STRATEGY FOR INNOVATION Source: Janssen
ABOUT YODA PROJECT Partnership with Yale School of Medicine - project aiming to provide open access to clinical trials data (YODA) to improve public health and to promote the progress of scientific knowledge. Based on an Independent Review Board that evaluates and grants access to clinical trials data for independent investigators to support scientific research. YALE OPEN DATA ACCESS PROJECT Source: Medtrack; Johnson & Johnson The Wall Street Journal
OUR CONTACT IN PORTUGAL José Antunes Medical Director & J&J Innovation Liaison Janssen-Cilag Farmacêutica, Lda Tel.: +351 91 2799 218 jantune1@its.jnj.com Source: Janssen
JANSSEN PARTNERSHIPS FOR INNOVATION IN HEALTH José Antunes Janssen Coimbra 16th April 2015